Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCHF DNA
- Development stage
- Unknown
- Lead developer
- SVF Vaccines
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
CCHF DNA is a DNA-based prophylactic vaccine candidate developed by SVF Vaccines for the prevention of Crimean-Congo Hemorrhagic Fever (CCHF). As a DNA vaccine, it is designed to deliver genetic sequences encoding viral antigens into host cells to stimulate an immune response against the CCHF virus. The project is identified by the developer as a precursor program with no current intellectual property (IP) associated and is listed as being in Phase 1 development.
Beyond the preview
Go deeper on CCHF DNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCHF DNA.